^
Association details:
| Biomarker: | MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Calquence (acalabrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
4265 Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study
Published date:
11/03/2022
Excerpt:
The RP2D ORR was 96% (95% CI 79-100) with 79% (95% CI 58-93) of pts. achieving a mCR (4 pts. partial response (PR), 1pts. stable disease (SD)). One pt. with MYC/BCL2/BCL6 rearrangements and 1 pt. with MYC/BCL6 rearrangement achieved a mCR; neither have progressed....Acalabrutinib is well tolerated in combination with R-CHOP chemotherapy and may be associated with improved efficacy.
Secondary therapy:
R-CHOP
DOI:
https://doi.org/10.1182/blood-2022-163499
